Customize View
Named by Company
Named by Competitor
Named by Third Party

Recently disclosed competitors only (within the last two years)
Include Competitors for:Current subsidiaries


Competitors

Recently Disclosed Competitors
Competitor's Name
LTM Revenue ($mm)
LTM Date
Source
Allergan plc
16,096.20
Mar-31-2020
Antares Pharma, Inc. 2020 Form 10-K
Business Description: Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, central nervous system, women’s health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; In addition, it develops medical and cosmetic treatments; treatments for neurodegenerative disorders; and inflammatory and fibrotic diseases. It has a collaboration, option, and license agreement with Lyndra, Inc. to develop orally administered products for the treatment of Alzheimer’s disease; strategic alliance and option agreement with Editas Medicine, Inc.; and Allergan plc also has licensing agreements with Assembly Biosciences, Inc. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was incorporated in 2013 and is headquartered in Dublin, Ireland. As of May 8, 2020, Allergan plc operates as a subsidiary of AbbVie Inc.
Antares Pharma, Inc.
183.46
Mar-31-2022
Acerus Pharmaceuticals Corporation - Form Doc
Business Description: Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company’s injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a subsidiary of Halozyme Therapeutics, Inc.
Bausch Health Companies Inc. (NYSE:BHC)
8,350.00
Jun-30-2023
Knight Therapeutics Inc. (TSX:GUD) - Form Doc
Business Description: Bausch Health Companies Inc. operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was incorporated in 2013 and is headquartered in Laval, Canada.
BGP Pharma ULC
1.11
-
Acerus Pharmaceuticals Corporation - Form Doc
Business Description: BGP Pharma ULC operates as a subsidiary of Viatris Inc.
Cipher Pharmaceuticals Inc. (TSX:CPH)
19.88
Jun-30-2023
Knight Therapeutics Inc. (TSX:GUD) - Form Doc
Business Description: Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company’s licensed products comprise Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne; Lipofe indicated as adjunctive therapy to diet to reduce triglycerides in adult patients with severe hypertriglyceridemia; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.
Clarus Therapeutics Holdings, Inc. (Out of Business)
16.91
Jun-30-2022
Acerus Pharmaceuticals Corporation - Form Doc
Business Description: Clarus Therapeutics Holdings, Inc. went out of business as its plan of liquidation became effective on February 28, 2023. Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
Eli Lilly and Company (NYSE:LLY)
29,515.50
Jun-30-2023
Antares Pharma, Inc. 2020 Form 10-K
Business Description: Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
HLS Therapeutics Inc. (TSX:HLS)
62.55
Jun-30-2023
Knight Therapeutics Inc. (TSX:GUD) - Form Doc
Business Description: HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; Vascepa, an icosapent ethyl capsules for cardiovascular disease; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the United States marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
Nuvo Pharmaceuticals Inc.
52.91
Sep-30-2022
Knight Therapeutics Inc. (TSX:GUD) - Form Doc
Business Description: Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet, a migraine medicine; NeoVisc, an injectable viscosupplement for osteoarthritis; and Resultz, FullMarks, and LAUSBUB for head lice infestations. The company also provides Bezalip SR for patients with high cholesterol or high levels of triglycerides; Proferrin, an iron supplement for the prevention and treatment of iron deficiency; Fiorinal 1 and Fiorinal C1 for the relief of tension-type headaches; Collatamp G for surgical implantation during surgery; PegaLAX, a laxative for the treatment of occasional constipation and irregularity; Mutaflor, a probiotic for the management and relief of chronic constipation and associated abdominal pain and cramps; MoviPrep for the cleansing of the colon in preparation for colonoscopy; and Soriatane to treat psoriasis and other keratinization disorders. In addition, it offers Pennsaid and Pennsaid 2% topical treatments for osteoarthritic pain; Vimovo for relief of arthritis symptoms; SYNERA and RAPYDAN topical patches used to help prevent pain associated with needle sticks and other superficial skin procedures; Yosprala for the prevention of heart attacks and strokes; and Heated Lidocaine/Tetracaine Patch, a topical patch applied prior to painful medical procedures. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was incorporated in 1983 and is headquartered in Mississauga, Canada. As of March 14, 2023, Nuvo Pharmaceuticals Inc. operates as a subsidiary of Searchlight Pharma Inc.
PendoPharm Inc.
-
-
Knight Therapeutics Inc. (TSX:GUD) - Form Doc
Business Description: PendoPharm Inc. develops, manufactures, licenses, and markets branded prescription medicines for health care professionals, pharmacists, and patients in Canada and internationally. It offers allergy, analgesics, cough, cold and sinus, gastroenterology, nasal care, and pediatrics products. It provides MYINFLA, a colchicine repurposed drug for the reduction of atherothrombotic events in adult patients. The company also offers specialty prescription products in therapeutic, such as gastroenterology, orthopedics, and urology. It sells its products through medical and retail sales representatives; wholesale and retail outlets, including pharmacy and mass grocery; affiliates; and distributors. PendoPharm Inc. was formerly known as Pangeo Pharma (Canada) Inc. and changed its name to PendoPharm Inc. in December 2004. The company was founded in 2003 and is based in Montreal, Canada. As of December 31, 2004, PendoPharm Inc. operates as a subsidiary of Pharmascience Inc.
Pharmascience Inc.
497.39
-
Knight Therapeutics Inc. (TSX:GUD) - Form Doc
Business Description: Pharmascience Inc. develops, manufactures, markets, and sells prescription, generic, over-the-counter (OTC), and behind-the-counter drug products. The company offers drugs for various therapeutic areas, including oncology, anti-infective, and cardiovascular; (Pr) pms-TRANDOLAPRIL, an angiotensin-converting enzyme inhibitor for the treatment of mild to moderate essential hypertension and the treatment following acute myocardial infarction; and (Pr)pms-PROGESTERONE, a progestin capsule for women with an intact uterus as an adjunct to postmenopausal estrogen replacement therapy to reduce the risk of endometrial hyperplasia and carcinoma. It also offers private label options for OTC drugs in various categories, such as pain management, cough and cold, stomach and gastro-intestinal ailments, and allergies to drug-store retail chains, grocery store banners, and distributors in Canada. In addition, the company offers services in the areas of medical equipment, advertising, and nursing services for pharmacists; and continuing education services. It serves pharmacists, drug wholesalers, retailers, and healthcare providers in Canada and internationally. The company was founded in 1983 and is based in Montreal, Canada with additional offices in Canada, Cyprus, Saudi Arabia, South Korea, Vietnam, and Ukraine. Pharmascience Inc. operates as a subsidiary of Joddes Limited.
Purdue Pharma Inc.
99.48
-
Knight Therapeutics Inc. (TSX:GUD) - Form Doc
Business Description: Purdue Pharma Inc. researches, develops, and manufactures over the counter and prescription medicines for pain management, attention deficit hyperactivity, and gastrointestinal disorders for patients and healthcare professionals in Canada. Its over the counter products include laxatives, decongestant, and antiseptics for the preparation of skin prior to surgery and injections. The company’s prescription medication comprises central nervous system stimulants, opioid analgesics, opioid antagonists, and bronchodilators. It also engages in the research in the field of drug delivery for the treatment of respiratory diseases, infection control, and urinary incontinence; sells buprenorphine buccal soluble films for the management of pain severe enough to require daily, continuous, long-term treatment, and opioid-responsive; and offers FOQUEST, a methylphenidate HCl controlled-release capsule used for the treatment of ADHD in adults. The company was founded in 1956 and is headquartered in Pickering, Canada. Purdue Pharma Inc. operates as a subsidiary of Purdue Pharma L.P. On September 15, 2019, Purdue Pharma Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. It is in joint administration with Purdue Pharma L.P. 
Sandoz International GmbH
172.48
-
Antares Pharma, Inc. 2020 Form 10-K
Business Description: Sandoz International GmbH develops biosimilars and generic antibiotics, and dermatology and transplantation medicines. The company offers solutions in various areas ranging from generic cardiovascular, central nervous system, pain, and ophthalmology to oncology, respiratory, and hormonal therapeutics. Its portfolio includes a range of technologies, formulations, and devices, including prolonged-release and multiple-unit tablets, creams and gels, orodispersible films, transdermal patches, lyophilized products, implants, and inhalers. In addition, the company offers Sandoz Pro, an application for healthcare professionals. It serves customers worldwide. The company was founded in 1886 and is based in Holzkirchen, Germany and additional location in Princeton, New Jersey. Sandoz International GmbH operates as a subsidiary of Sandoz Group AG (SWX:SDZ).
Taro Pharmaceuticals Inc.
182.71
-
Acerus Pharmaceuticals Corporation - Form Doc
Business Description: Taro Pharmaceuticals Inc., a pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products. The company provides generic products, as well as private label and branded drugs; topical dermatological products, such as creams, ointments, and gels; and solid dosage form products that include tablets and capsules. Its customers include wholesalers, drugstore chains, grocery chains, mass volume retailers, healthcare institutions, independent drug stores, and discount retailers in Canada and internationally. The company was founded in 1984 and is based in Brampton, Canada. Taro Pharmaceuticals Inc. operates as a subsidiary of Taro Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
15,017.00
Jun-30-2023
Antares Pharma, Inc. 2020 Form 10-K
Business Description: Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company’s products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington’s disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration with MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia, as well as a collaboration with Sanofi to co-develop and co-commercialize TEV-48574 asset, a novel anti-TL1A therapy for the treatment of ulcerative colitis and Crohn’s disease. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
Valeant Canada Ltd.
48.28
-
Knight Therapeutics Inc. (TSX:GUD) - Form Doc
Business Description: Valeant Canada Ltd., a specialty pharmaceutical company, manufactures, distributes, and markets pharmaceutical products in the fields of neurology, psychiatry, pain management, and dermatology. It also focuses on neurology, such as pain management, Parkinson's disease, Epilepsy, multiple sclerosis, Huntington's disease, and ALS; infectious diseases, which include Hepatitis, HIV, SARS, and RSV; Dermatology, including Psoriasis, Eczema, Acne, Rosacea, Actinic Keratoses, Squamous Cell Carcinoma, and anti-fungals; and sleep disorders. Valeant Canada Ltd. was formerly known as ICN Canada Ltd and changed its name to Valeant Canada Ltd. in September 2004. The company was founded in 1956 and is based in Montreal, Canada. Valeant Canada Ltd. operates as a subsidiary of Valeant Pharmaceuticals International, Inc.
Viatris Inc. (NasdaqGS:VTRS)
15,601.90
Jun-30-2023
Antares Pharma, Inc. 2020 Form 10-K
Business Description: Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
*denotes proprietary relationship